Liminatus Pharma, Inc. LIMN
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 76.61% | -- | -- | -- | 127.02% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 94.27% | -- | -- | -- | -53.72% |
| Operating Income | -94.27% | -- | -- | -- | 53.72% |
| Income Before Tax | -1,097.94% | -- | -- | -- | 77.65% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1,097.94% | -- | -- | -- | 77.65% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1,097.94% | -- | -- | -- | 77.65% |
| EBIT | -94.27% | -- | -- | -- | 53.72% |
| EBITDA | -263.49% | -- | -- | -- | -- |
| EPS Basic | -599.68% | -- | -- | -- | 64.46% |
| Normalized Basic EPS | -53.80% | -- | -- | -- | 29.99% |
| EPS Diluted | -599.68% | -- | -- | -- | 64.46% |
| Normalized Diluted EPS | -53.80% | -- | -- | -- | 29.99% |
| Average Basic Shares Outstanding | 82.73% | -- | -- | -- | -70.82% |
| Average Diluted Shares Outstanding | 82.73% | -- | -- | -- | -70.82% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |